<DOC>
	<DOC>NCT00750425</DOC>
	<brief_summary>Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.</brief_summary>
	<brief_title>Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Written informed consent Histological or cytological confirmation of advanced solid tumour (with the exception of prostate cancer), which is refractory to standard therapies or for which no standard therapy exists. Estimated life expectancy of at least 8 weeks WHO performance status (PS) 02. Unstable brain/meningeal metastases Biochemistry/haematology results outside of required ranges History of significant GI impairment Inadequate bone marrow reserve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>advanced cancer,</keyword>
	<keyword>metastatic</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
</DOC>